Non-lipidated variants of
View Patent ↗The present invention relates to compositions including an isolated non-pyruvylated non-lipidated ORF2086 polypeptide, and methods thereof. In an exemplary embodiment, the compositions described herein are immunogenic. The present invention further relates to compositions that elicit a bactericidal immune response in a mammal against an ORF2086 subfamily B polypeptide from serogroup B Neisseria meningitidis , and methods related thereto.
1. An immunogenic composition comprising an immunologically effective amount of a first non-pyruvylated non-lipidated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 50, wherein the first non-pyruvylated non-lipidated polypeptide lacks cysteine at the N-terminus of SEQ ID NO: 50 and does not exhibit a mass shift of +70 Da compared to the corresponding wild-type non-lipidated polypeptide as measured by mass spectrometry.
2. The immunogenic composition of claim 1 , further comprising an immunologically effective amount of a second non-pyruvylated non-lipidated polypeptide having the amino acid sequence set forth in SEQ ID NO: 44, wherein the second non-pyruvylated non-lipidated polypeptide lacks cysteine at the N-terminus of SEQ ID NO: 44 and does not exhibit a mass shift of +70 Da compared to the corresponding wild-type non-lipidated polypeptide as measured by mass spectrometry.
3. The immunogenic composition of claim 2 , wherein the first non-pyruvylated non-lipidated polypeptide is encoded by a nucleotide sequence comprising SEQ ID NO: 45.
4. The immunogenic composition of claim 1 , further comprising an immunologically effective amount of a non-lipidated N. meningitidis , serogroup B, 2086 Subfamily A polypeptide.
5. The immunogenic composition of claim 4 , wherein the Subfamily A polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 55.
6. The immunogenic composition of claim 1 , further comprising an immunologically effective amount of a second non-pyruvylated non-lipidated polypeptide having the amino acid sequence set forth in SEQ ID NO: 57, wherein the second non-pyruvylated non-lipidated polypeptide lacks cysteine at the N-terminus of SEQ ID NO: 57 and does not exhibit a mass shift of +70 Da compared to the corresponding wild-type non-lipidated polypeptide as measured by mass spectrometry.
7. The immunogenic composition of claim 1 , further comprising an immunologically effective amount of a second non-pyruvylated non-lipidated polypeptide having the amino acid sequence set forth in SEQ ID NO: 58, wherein the second non-pyruvylated non-lipidated polypeptide lacks cysteine at the N-terminus of SEQ ID NO: 58 and does not exhibit a mass shift of +70 Da compared to the corresponding wild-type non-lipidated polypeptide as measured by mass spectrometry.
8. The immunogenic composition of claim 1 , further comprising an immunologically effective amount of a second non-pyruvylated non-lipidated polypeptide having the amino acid sequence set forth in SEQ ID NO: 59, wherein the second non-pyruvylated non-lipidated polypeptide lacks cysteine at the N-terminus of SEQ ID NO: 59 and does not exhibit a mass shift of +70 Da compared to the corresponding wild-type non-lipidated polypeptide as measured by mass spectrometry.
9. The immunogenic composition of claim 1 , further comprising an immunologically effective amount of a second non-pyruvylated non-lipidated polypeptide having the amino acid sequence set forth in SEQ ID NO: 60, wherein the second non-pyruvylated non-lipidated polypeptide lacks cysteine at the N-terminus of SEQ ID NO: 60 and does not exhibit a mass shift of +70 Da compared to the corresponding wild-type non-lipidated polypeptide as measured by mass spectrometry.
10. The immunogenic composition of claim 1 , further comprising an immunologically effective amount of a second non-pyruvylated non-lipidated polypeptide having the amino acid sequence set forth in SEQ ID NO: 62, wherein the second non-pyruvylated non-lipidated polypeptide lacks cysteine at the N-terminus of SEQ ID NO: 62 and does not exhibit a mass shift of +70 Da compared to the corresponding wild-type non-lipidated polypeptide as measured by mass spectrometry.
11. The immunogenic composition of claim 1 , further comprising an immunologically effective amount of a second non-pyruvylated non-lipidated polypeptide having the amino acid sequence set forth in SEQ ID NO: 64, wherein the second non-pyruvylated non-lipidated polypeptide lacks cysteine at the N-terminus of SEQ ID NO: 64 and does not exhibit a mass shift of +70 Da compared to the corresponding wild-type non-lipidated polypeptide as measured by mass spectrometry.